Chong Woo Chu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Chong Woo Chu has a total of 44 co-authors. Here are the top co-authors by number of shared publications:
B.H. Choi
Division of Hepato-Biliary-Pancreatic Surgery and Transplantation, Department of Surgery, Pusan National University Yangsan Hospital, Yangsan, Korea
5 shared publicationsJ.H. Ryu
Division of Hepato-Biliary-Pancreatic Surgery and Transplantation, Department of Surgery, Pusan National University Yangsan Hospital, Yangsan, Korea
5 shared publicationsY.M. Park
Division of Hepato-Biliary-Pancreatic Surgery and Transplantation, Department of Surgery, Pusan National University Yangsan Hospital, Yangsan, Korea
5 shared publicationsK.H. Yang
Division of Hepato-Biliary-Pancreatic Surgery and Transplantation, Department of Surgery, Pusan National University Yangsan Hospital, Pusan National University School of Medicine, Yangsan, Korea
4 shared publicationsH.Y. Lee
Division of Hepato-Biliary-Pancreatic Surgery and Transplantation, Department of Surgery, Pusan National University Yangsan Hospital, Pusan National University School of Medicine, Yangsan, Korea
3 shared publications- Chang-Jin Kim
Changwon Hanmaeum Hospital, Uichang-gu, Changwon-si 51139, Gyeongsangnam-do, Republic of Korea
1 shared publication
Latest Publications
- Open Access
- 17 February 2025
- Published by MDPI AG in Current Oncology
- Vol. 32 (2) , 114
TM7SF2 as a Potential Biomarker in Colorectal Cancer: Implications for Metastasis
Colorectal cancer (CRC) is a commonly fatal cancer and ranks as the fourth most prevalent in men and third in women worldwide. While early-stage survival rates are high, they significantly decrease with recurrence and metastasis. Thus, the early detection and treatment of metastasis-related factors can significantly improve survival rates. In this study, the transmembrane 7 superfamily member 2 (TM7SF2) gene was validated as a biomarker for predicting metastasis in CRC. Immunohistochemical staining was performed on 236 CRC tissues, and the clinicopathological factors of patients with CRC were analyzed. This evaluation revealed that TM7SF2 expression is associated with the clinical stage. Kaplan–Meier analysis confirmed the relationship between the survival rate of CRC patients and TM7SF2 expression, showing a decrease in survival rate with TM7SF2 overexpression (log-rank, p < 0.001). TM7SF2 expression was also confirmed in two pairs of primary and metastatic cell lines (SW480 and SW620). TM7SF2 knockdown was executed using siRNAs in SW480 and SW620 cells, which exhibit high expression levels. The knockdown was verified using RT-PCR and immunoblotting. Functional studies investigated the effects of TM7SF2 on cell proliferation, migration, invasion, and colony formation, revealing that all these functions were suppressed in the CRC cell lines following TM7SF2 knockdown. Therefore, TM7SF2 shows promise as a biomarker for the prevention of colorectal cancer.
- 17 February 2025
- Published by MDPI AG in Current Oncology
- Vol. 32 (2) , 114
Open AccessTM7SF2 as a Potential Biomarker in Colorectal Cancer: Implications for Metastasis
Colorectal cancer (CRC) is a commonly fatal cancer and ranks as the fourth most prevalent in men and third in women worldwide. While early-stage survival rates are high, they significantly decrease with recurrence and metastasis. Thus, the early detection and treatment of metastasis-related factors can significantly improve survival rates. In this study, the transmembrane 7 superfamily member 2 (TM7SF2) gene was validated as a biomarker for predicting metastasis in CRC. Immunohistochemical staining was performed on 236 CRC tissues, and the clinicopathological factors of patients with CRC were analyzed. This evaluation revealed that TM7SF2 expression is associated with the clinical stage. Kaplan–Meier analysis confirmed the relationship between the survival rate of CRC patients and TM7SF2 expression, showing a decrease in survival rate with TM7SF2 overexpression (log-rank, p < 0.001). TM7SF2 expression was also confirmed in two pairs of primary and metastatic cell lines (SW480 and SW620). TM7SF2 knockdown was executed using siRNAs in SW480 and SW620 cells, which exhibit high expression levels. The knockdown was verified using RT-PCR and immunoblotting. Functional studies investigated the effects of TM7SF2 on cell proliferation, migration, invasion, and colony formation, revealing that all these functions were suppressed in the CRC cell lines following TM7SF2 knockdown. Therefore, TM7SF2 shows promise as a biomarker for the prevention of colorectal cancer.
- Open Access
- 8 September 2020
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 9 (9) , 2897
Effect of CYP3A5 on the Once-Daily Tacrolimus Conversion in Stable Liver Transplant Patients
Cytochrome P450 (CYP) 3A5 polymorphism influences tacrolimus metabolism, but its effect on the drug pharmacokinetics in liver transplant recipients switched to once-daily extended-release formulation remains unknown. The aim of this study is to analyze the effect of CYP3A5 polymorphism on liver function after once-daily tacrolimus conversion in liver transplant patients. A prospective open-label study included 60 stable liver transplant recipients who underwent 1:1 conversion from twice-daily tacrolimus to once-daily tacrolimus. All participants were genotyped for CYP3A5 polymorphism. The study was registered at ClinicalTrials.gov (NCT 02882113). Twenty-eight patients were enrolled in the CYP3A5 expressor group and 32 in the non-expressor group. Although there was no statistical difference, incidence of liver dysfunction was higher in the expressor group than in the non-expressor group when converted to once-daily extended-release tacrolimus (p = 0.088). No biopsy-proven acute rejection, graft failure, and mortality were observed in either group. The decrease in dose-adjusted trough level (−42.9% vs. −26.1%) and dose/kg-adjusted trough level of tacrolimus (−40.0% vs. −23.7%) was significantly greater in the expressor group than in the non-expressors after the conversion. A pharmacokinetic analysis was performed in 10 patients and tacrolimus absorption in the non-expressor group was slower than in the expressor group. In line with this observation, the area under the curve for once-daily tacrolimus correlated with trough level (Cmin) in the non-expressors and peak concentration (Cmax) in the expressors. CYP3A5 genotyping in liver transplant recipients leads to prediction of pharmacokinetics after switching from a twice-daily regimen to a once-daily dosage form, which makes it possible to establish an appropriate dose of tacrolimus.
- 8 September 2020
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 9 (9) , 2897
Open AccessEffect of CYP3A5 on the Once-Daily Tacrolimus Conversion in Stable Liver Transplant Patients
Cytochrome P450 (CYP) 3A5 polymorphism influences tacrolimus metabolism, but its effect on the drug pharmacokinetics in liver transplant recipients switched to once-daily extended-release formulation remains unknown. The aim of this study is to analyze the effect of CYP3A5 polymorphism on liver function after once-daily tacrolimus conversion in liver transplant patients. A prospective open-label study included 60 stable liver transplant recipients who underwent 1:1 conversion from twice-daily tacrolimus to once-daily tacrolimus. All participants were genotyped for CYP3A5 polymorphism. The study was registered at ClinicalTrials.gov (NCT 02882113). Twenty-eight patients were enrolled in the CYP3A5 expressor group and 32 in the non-expressor group. Although there was no statistical difference, incidence of liver dysfunction was higher in the expressor group than in the non-expressor group when converted to once-daily extended-release tacrolimus (p = 0.088). No biopsy-proven acute rejection, graft failure, and mortality were observed in either group. The decrease in dose-adjusted trough level (−42.9% vs. −26.1%) and dose/kg-adjusted trough level of tacrolimus (−40.0% vs. −23.7%) was significantly greater in the expressor group than in the non-expressors after the conversion. A pharmacokinetic analysis was performed in 10 patients and tacrolimus absorption in the non-expressor group was slower than in the expressor group. In line with this observation, the area under the curve for once-daily tacrolimus correlated with trough level (Cmin) in the non-expressors and peak concentration (Cmax) in the expressors. CYP3A5 genotyping in liver transplant recipients leads to prediction of pharmacokinetics after switching from a twice-daily regimen to a once-daily dosage form, which makes it possible to establish an appropriate dose of tacrolimus.
- 1 December 2016
- Published by Elsevier in Transplantation Proceedings
- Vol. 48 (10) , 3317-3322
Development and Applicability of the A-P 200 Criteria for Liver Transplantation for Hepatocellular Carcinoma
- 1 December 2016
- Published by Elsevier in Transplantation Proceedings
- Vol. 48 (10) , 3317-3322
Development and Applicability of the A-P 200 Criteria for Liver Transplantation for Hepatocellular Carcinoma
- 1 September 2016
- Published by Elsevier in Transplantation Proceedings
- Vol. 48 (7) , 2458-2460
Beneficial Effect of Extracorporeal Membrane Oxygenation on Organ Perfusion During Management of the Unstable Brain-dead Donor: A Case Series
- 1 September 2016
- Published by Elsevier in Transplantation Proceedings
- Vol. 48 (7) , 2458-2460
Beneficial Effect of Extracorporeal Membrane Oxygenation on Organ Perfusion During Management of the Unstable Brain-dead Donor: A Case Series
- 1 January 2016
- Published by Elsevier in Transplantation Proceedings
- Vol. 48 (1) , 247-250
Complete Regression of Recurrent Advanced Hepatocellular Carcinoma After Liver Transplantation in Response to Sorafenib Treatment: A Case Report
- 1 January 2016
- Published by Elsevier in Transplantation Proceedings
- Vol. 48 (1) , 247-250
Complete Regression of Recurrent Advanced Hepatocellular Carcinoma After Liver Transplantation in Response to Sorafenib Treatment: A Case Report
- 1 January 2016
- Published by Elsevier in Transplantation Proceedings
- Vol. 48 (1) , 242-246
Irreversible Graft Failure Requiring 3 Repeated Liver Transplantations Combined With a 2-Stage Liver Transplantation: A Case Report
- 1 January 2016
- Published by Elsevier in Transplantation Proceedings
- Vol. 48 (1) , 242-246
Irreversible Graft Failure Requiring 3 Repeated Liver Transplantations Combined With a 2-Stage Liver Transplantation: A Case Report
- 8 September 2015
- Published by Elsevier in Transplantation Proceedings
- Vol. 47 (7) , 2270-2273
Formation of Collateral Veins in a Graft Pancreas After a Simultaneous Pancreas and Kidney Transplantation: A Case Report
- 8 September 2015
- Published by Elsevier in Transplantation Proceedings
- Vol. 47 (7) , 2270-2273
Formation of Collateral Veins in a Graft Pancreas After a Simultaneous Pancreas and Kidney Transplantation: A Case Report
- Open Access
- 1 January 2014
- Published by The Korean Surgical Society in Annals of Surgical Treatment and Research
- Vol. 87 (4) , 185-191
Caudal middle hepatic vein trunk preserved right lobe graft in living donor liver transplantation
Yang K, et al. Ann Surg Treat Res. 2014 Oct;87(4):185-191. http://dx.doi.org/10.4174/astr.2014.87.4.185
- 1 January 2014
- Published by The Korean Surgical Society in Annals of Surgical Treatment and Research
- Vol. 87 (4) , 185-191
Open AccessCaudal middle hepatic vein trunk preserved right lobe graft in living donor liver transplantation
Yang K, et al. Ann Surg Treat Res. 2014 Oct;87(4):185-191. http://dx.doi.org/10.4174/astr.2014.87.4.185
- Open Access
- 1 January 2012
- Published by The Korean Surgical Society in Journal of the Korean Surgical Society
- Vol. 82 (2) , 128-133
More than 7-year survival of a patient following repeat hepatectomy for total 20 colon cancer liver metastases
Yang KH, et al. J Korean Surg Soc. 2012 Feb;82(2):128-133. http://dx.doi.org/10.4174/jkss.2012.82.2.128
- 1 January 2012
- Published by The Korean Surgical Society in Journal of the Korean Surgical Society
- Vol. 82 (2) , 128-133
Open AccessMore than 7-year survival of a patient following repeat hepatectomy for total 20 colon cancer liver metastases
Yang KH, et al. J Korean Surg Soc. 2012 Feb;82(2):128-133. http://dx.doi.org/10.4174/jkss.2012.82.2.128